Protocol of a randomised controlled trial in cardiac surgical patients with endothelial dysfunction aimed to prevent postoperative acute kidney injury by administering nitric oxide gas

Francesco Marrazzo,1 Stefano Spina,1 Francesco Zadek,1 Tenzing Lama,1 Changhan Xu,1 Grant Larson,1 Emanuele Rezoagli,1 Rajeev Malhotra,2 Hui Zheng,3 Edward A Bittner,1 Kenneth Shelton,1 Serguei Melnitchouk,4 Nathalie Roy,4 Thoralf M Sundt,4 William D Riley,5 Purris Williams,6 Daniel Fisher,7 Robert M Kacmarek,8,9 Taylor B Thompson,10 Joseph Bonventre,11 Warren Zapol,1 Fumito Ichinose,1 Lorenzo Berra1

ABSTRACT

Introduction Postoperative acute kidney injury (AKI) is a common complication in cardiac surgery. Levels of intravascular haemolysis are strongly associated with postoperative AKI and with prolonged (>90 min) use of cardiopulmonary bypass (CPB). Ferrous plasma haemoglobin released into the circulation acts as a scavenger of nitric oxide (NO) produced by endothelial cells. Consequently, the vascular bioavailability of NO is reduced, leading to vasoconstriction and impaired renal function. In patients with cardiovascular risk factors, the endothelium is dysfunctional and cannot replenish the NO deficit. A previous clinical study in young cardiac surgical patients with rheumatic fever, without evidence of endothelial dysfunction, showed that supplementation of NO gas decreases AKI by converting ferrous plasma haemoglobin to ferric methaemoglobin, thus preserving vascular NO. In this current trial, we hypothesised that 24 hours administration of NO gas will reduce AKI following CPB in patients with endothelial dysfunction.

Methods This is a single-centre, randomised (1:1) controlled, parallel-arm superiority trial that includes patients with endothelial dysfunction, stable kidney function and who are undergoing cardiac surgery procedures with an expected CPB duration >90 min. After randomisation, 80 parts per million (ppm) NO (intervention group) or 80 ppm nitrogen (N2, control group) are added to the gas mixture. Test gases (N2 or NO) are delivered during randomisation, 80 parts per million (ppm) NO (intervention group) or 80 ppm nitrogen (N2, control group) are added to the gas mixture. Test gases (N2 or NO) are delivered during

Strengths and limitations of this study

▸ Supplementation with nitric oxide (NO) gas during and after surgery requiring prolonged cardiopulmonary bypass might be most beneficial to those patients with endothelial dysfunction who are unable to replace the haemolysis-mediated NO depletion due to an impaired endothelial nitric oxide synthase (eNOS) activity.

▸ The number of confounding variables resulting from the liberal use of nephrotoxic agents, the preoperative variability in serum creatinine level and the perioperative optimisation of haemodynamics and volume status is minimised, since the “Kidney Disease: Improving Global Outcomes” guidelines for renal protection are a standard of care at our institution.

▸ Results from this study could possibly be generalised to other clinical scenarios of intravascular haemolysis and vascular depletion of NO.

▸ This trial is designed to recruit patients from a single academic institution (Massachusetts General Hospital).

INTRODUCTION

Acute kidney injury (AKI) is a common and serious complication after cardiac surgery procedures requiring prolonged (>90 min) cardiopulmonary bypass (CPB).1–3 Because postcardiac surgical AKI is associated with increased risk of chronic kidney disease (CKD) and mortality,4–6 multiple
interventions have been tested in large multicentre trials, but none have been successful at reducing AKI.\textsuperscript{7}–\textsuperscript{10}

There are two major categories of risk factors for postsurgical AKI. The first is the patient’s cardiovascular comorbidities that are associated with impaired endothelial function. These include obesity, diabetes, atherosclerosis, peripheral vascular disease, hyperlipidaemia, smoking and hypertension.\textsuperscript{2,11} The second is the extent of CPB-associated haemolysis.\textsuperscript{12}–\textsuperscript{15} During haemolysis, plasma haemoglobin (Hb) is released into the circulation and depletes plasma nitric oxide (NO).\textsuperscript{16,17} NO is a potent mediator of vasodilation and regulates blood flow to tissues.\textsuperscript{18} In patients with endothelial dysfunction, the activity of endothelial NO synthase (eNOS), the enzyme responsible for NO production, is impaired and is unable to replenish the NO consumed by plasma Hb.\textsuperscript{19}–\textsuperscript{21}

In an animal model of free water-induced intravascular haemolysis, Minneci et al. showed that haemolysis resulted in a reduction of creatinine clearance. The negative effects of haemolysis on renal function were attenuated by the inhalation of 80 parts per million (ppm) NO gas. NO oxidised plasma Oxy-Hb (Fe\textsuperscript{2+}) to ferric methaemoglobin (Met-Hb, Fe\textsuperscript{3+}), thereby decreasing plasma NO consumption.\textsuperscript{16} In a meta-analysis, the administration of NO gas has been associated with increased risk of AKI in critically ill patients with acute respiratory distress syndrome (ARDS), especially with prolonged use.\textsuperscript{22} However, no studies have shown an association between NO administration and increased incidence of AKI in paediatric or adult cardiac surgery population.

In a recent randomised controlled trial (RCT), administration of 80 ppm NO gas for 24 hours, starting at the onset of CPB, was found to decrease postoperative AKI in a population of young Chinese cardiac surgical patients (average age 48), with no risk factors for endothelial dysfunction, who were undergoing cardiac valve replacement due to rheumatic heart disease.\textsuperscript{17} NO administration also improved long-term outcomes such as major adverse kidney events (MAKE) and reduced stage 3 CKD for up to 1 year after surgery. However, it is still undetermined whether NO gas exerts similar, or even additional, renal protective effects in patients with endothelial dysfunction commonly treated in the USA.

METHODS AND ANALYSIS

Trial design

In this, single-centre, randomised (1:1) controlled, parallel-arm superiority trial, we hypothesised that 24 hours administration of NO gas starting from the initiation of CPB will decrease AKI by converting Oxy-Hb to Met-Hb in patients with signs and symptoms of endothelial dysfunction suggestive of impaired activity of eNOS (primary outcome).

After screening, consented patients who meet the enrolment criteria are randomised to receive either 80 ppm NO (intervention group, n=125) or nitrogen (N\textsubscript{2}, control group, n=125) for 24 hours as N\textsubscript{2} is the major component of air and can be used as placebo. The test gas is administered via the oxygenator during CPB, then by inhalation once mechanical ventilation is resumed. When the patient is extubated, the test gas is delivered by high flow nasal cannula. On the day of surgery, after the insertion of a pulmonary artery catheter (PAC), patients are stratified by preoperative mean pulmonary artery pressure (mPAP) (ie, mPAP <30 mm Hg or mPAP \geq 30 mm Hg) then allocated into the two study groups. Consent patients, with mPAP found to be \geq 40 mm Hg on the day of surgery after PAC placement, are not randomised in this study because NO or other pulmonary vasodilators might be indicated as part of the medical treatment during the perioperative period. Study outcomes are assessed during the hospital
In order to avoid postoperative AKI, at our institution, the 'Kidney Disease: Improving Global Outcomes (KDIGO) guidelines' are the standard of care in all cardiac surgical patients.23 The implementation of these guidelines has been shown to limit the incidence and severity of CPB-associated AKI.24 Per these guidelines, patients do not receive any nephrotoxic agents such as intravenous contrast agents25 during the first 48 hours after surgery. Patients receive close monitoring of serum creatinine and hourly urine output and avoid intraoperative and postoperative hyperglycaemia for at least 72 hours after surgery. Haemodynamics are closely monitored to maintain adequate cardiac output (CO) and blood pressure by using intraoperative transoesophageal echocardiography (TEE) in combination with the PAC and a radial artery catheter.23 24 The pulmonary and radial artery catheters are removed only after the patient is discharged from the intensive care unit (ICU) and after completion of test gas treatment.

In order to avoid postoperative AKI, at our institution, the 'Kidney Disease: Improving Global Outcomes (KDIGO) guidelines' are the standard of care in all cardiac surgical patients.23 The implementation of these guidelines has been shown to limit the incidence and severity of CPB-associated AKI.24 Per these guidelines, patients do not receive any nephrotoxic agents such as intravenous contrast agents during the first 48 hours after surgery. Patients receive close monitoring of serum creatinine and hourly urine output and avoid intraoperative and postoperative hyperglycaemia for at least 72 hours after surgery. Haemodynamics are closely monitored to maintain adequate cardiac output (CO) and blood pressure by using intraoperative transoesophageal echocardiography (TEE) in combination with the PAC and a radial artery catheter.23 24 The pulmonary and radial artery catheters are removed only after the patient is discharged from the intensive care unit (ICU) and after completion of test gas treatment.

The study enrolment opened in February 2017 and the first patient entered the trial in June 2017. The study team plans to enrol 250 patients over a period of 3 years. The study design is depicted in figure 1.

### Eligibility criteria

The study population includes men aged >40 years and women aged >50 years who have signs and symptoms of endothelial dysfunction, have stable kidney function in the 3 months prior to surgery, are undergoing cardiac surgery procedures with expected prolonged CPB (>90 min) and are not currently enrolled in other research studies. The presence of endothelial dysfunction is evaluated by using a brief questionnaire that integrates medical history with clinical and laboratory data that have previously been associated with endothelial dysfunction (figure 2).26–35 Eligible patients are those undergoing a scheduled procedure or patients who are already admitted to the hospital. Key exclusion criteria include estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m², mPAP ≥40 mm Hg and intravenous contrast infusion within 48 hours before surgery. A complete list of enrolment criteria is provided in box 1.

### Intervention

**Perioperative management**

Perioperative management including the implementation of the KDIGO guidelines has been shown to decrease the incidence of postcardiac surgical AKI.24 These guidelines recommend the avoidance of nephrotoxic agents, the
Box 1  Inclusion and exclusion criteria

**Inclusion criteria:**
1. Age ≥18 years.
2. Elective cardiac or aortic surgery requiring CPB and with expected CPB >90 min.
3. Clinical evidence of endothelial dysfunction assessed by a specifically designed questionnaire (figure 2).
4. Stable preoperative renal function without evidence of a plasma creatinine increase of ≥0.3 mg/dL within 3 months of study entry and without receiving RRT.

**Exclusion criteria:**
1. eGFR less than 30 mL/min/1.73 m².
2. Emergency cardiac surgery.
3. Life expectancy <1 year at the time of enrolment.
4. mPAP ≥40 mm Hg and PVR >4 Wood Units.
5. LVEF <30% by echocardiography obtained within 3 months of enrolment.
6. Haemodynamic instability on the day of surgery as defined by a SBP <90 mm Hg.
7. Administration of one or more pRBC transfusion in the week prior to enrolment.
8. X-ray contrast infusion less than 48 hours before surgery.
9. Evidence of intravascular or extravascular haemolysis from any other origin:
   - Intravascular: intrinsic RBC defects leading to haemolytic anaemia (eg, enzyme deficiencies, haemoglobinopathies, membrane defects).
   - Extravascular: infection (eg, clostridial sepsis, severe malaria), paroxysmal cold haemoglobinuria, cold agglutinin disease, paroxysmal nocturnal haemoglobinuria, intravenous infusion of Rho (D) immune globulin, intravenous infusion of hypotonic solutions.

CPB, cardiopulmonary bypass; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; mPAP, mean pulmonary artery pressure; pRBC, packed red blood cells; PVR, pulmonary vascular resistance; RRT, renal replacement therapy; SBP, systolic blood pressure.

continuously recorded. A radial arterial catheter (Arrow Seldinger Arterial Catheter) is placed for continuous blood pressure monitoring and blood sampling. Patients are then preoxygenated at an inspired oxygen concentration of 100% for 3 min. Anaesthesia is then induced with an intravenous bolus injection of 4–6 µg/kg of fentanyl and either propofol 2 mg/kg or etomidate 0.1 mg/kg. Rocuronium 1.2 mg/kg or cisatracurium 0.2 mg/kg are used for paralysis prior to orotracheal intubation. Medication doses are adjusted in elderly patients. After intubation, patients are connected to the anaesthesia machine, and mechanical ventilation is delivered in volume-controlled mode with a tidal volume of 6 mL/kg. Respiratory rate is titrated to maintain a partial pressure of carbon dioxide (PaCO₂) between 35 and 45 mm Hg. The inspired fraction of oxygen (FiO₂) is titrated according to the partial pressure of oxygen (PaO₂), which is measured with arterial blood gas analysis. The TEE probe (X7-2t 3D ultrasound probe, Philips) is inserted by the cardiac-anaesthesia team for real-time intraoperative feedback to cardiac surgeons on (1) right and left ventricular function, (2) the mechanical stability and the function of repaired/replaced heart valves and (3) the detection of air emboli/clots. The neck, chest and abdomen are prepped and draped in a sterile fashion. A urinary catheter is positioned for hourly urinary output monitoring. To determine intraoperative and postoperative effects of NO on haemodynamics, after induction of anaesthesia, a PAC (Edwards Lifescience, Irvine, California, USA) is placed in all patients for continuous haemodynamic monitoring of central venous pressure (CVP), pulmonary artery pressure (PAP) and cardiac index (CI). Electrodes for SEDLine brain function monitoring (Masimo, Irvine, California, USA) are positioned on the forehead of each patient to assess the depth of anaesthesia by displaying frontal cortex electroencephalogram waveforms and measuring the patient state index (PSI). The level of anaesthesia is maintained by isoflurane administration (0.8–1.2 minimum alveolar concentration) and adjusted based on haemodynamics, while sustaining a PSI score between 30 and 50. Paralysis is maintained throughout the entire procedure by continuous infusion of rocuronium 4–10 µg/kg/min or cisatracurium 1–3 µg/kg/min. When clinically indicated, inotropes or vasopressors are administered to maintain a mean arterial pressure (MAP) >65 mm Hg and a CI >2.2 L/min/m².

The perfusion equipment utilised at Massachusetts General Hospital consists of Stockert S5 (LivaNova,米兰多拉, Italy) heart–lung machines, CardioQuip (CardioQuip, Bryan, Texas, USA) cooler heaters, the LivaNova Xtra autologous cell salvage system and Medtronic HMS Plus Hepon system (Medtronic, Minneapolis, Minnesota, USA).

The CPB circuit is primed with 1600 mL Ringer’s lactate and recirculated for priming and air removal. Prior to cannulation, the patient is fully heparinised to a target activated clotting time (ACT) of no less than 400s and a target heparin concentration of no less than 2.0 IU/mL. The loading dose of heparin is calculated by the Hepon device and subsequent ACT and heparin concentration continuously.
assays are performed on the same system. The cannulation strategy may be central, peripheral or a combination of both depending on the type of surgery (coronary/valve vs aortic), level of urgency, surgical approach (median sternotomy vs thoracotomy), patient-specific variables such as body habitus, previous cardiac surgical history, vascular disease and vascular anatomic anomalies. Most commonly, an arterial outflow cannula is placed in the distal ascending aorta and venous drainage is achieved by placing a multistage venous cannula in the right atrium via the inferior vena cava. The aortic root is typically cannulated with a catheter to deliver antegrade cardioplegia as well as to decompress the left ventricle. Retrograde catheters are commonly placed in the coronary sinus to maximise myocardial protection during the aortic cross clamp.

Once fully cannulated and prior to CPB, 500 mL–1000 mL of prime volume may be removed from the CPB circuit via retrograde autologous priming and/or venous antegrade priming to reduce the crystalloid burden on the patient on initiation of CPB. Once the patient is placed on CPB hypothermia is initiated to an extent dictated by type of surgery and surgeon’s preference. Mild hypothermia (temperature maintained between 32°C and 35°C) is most common for coronary and valve operations whereas circulatory arrest cases call for deeper hypothermia (temperature maintained between 18°C and 24°C).

Aortic occlusion is achieved by application of an aortic cross clamp and myocardial protection is achieved by administration of either Del Nido cardioplegia or a traditional 4:1 (blood:crystalloid) mixture at hypothermia into the aortic root (antegrade) and the coronary sinus (retrograde). Diastolic arrest is maintained by intermittent doses of cardioplegia every 20–30 min.

Blood flow rates while on CPB are maintained at a CI of 2.4–4.0 L/min/m² or greater, a MAP of 65–75 mm Hg and a urinary output of greater than 0.5 mL/kg/hour. To achieve these MAP goals, phenylephrine may be titrated to effect and diuretics such as furosemide (10 mg bolus) may be given. Sweep gas flow and FiO₂ are regulated to maintain a PaO₂ of 150–250 mm Hg and a mixed venous oxygen saturation (SvO₂) greater than 65%.

Arterial and venous blood gases are drawn every 30 min and analysed by the hospital laboratory. Ultrafiltration with a LivaNova hemoconcentrator (LivaNova, Mirandola, Italy) may be performed with or without maintaining zero balance fluid administration for the purposes of normalising potassium levels (target K⁺ 3.5–5.5 mmol/L) and to increase haematocrit (HCT) (target HCT greater than 21%), respectively. In the event, ultrafiltration is inadequate to increase HCT to greater than 21% packed red blood cells (pRBCs) or red blood cells processed by intraoperative autotransfusion may be administered via the LivaNova Xtra autologous cell salvage system. Target blood glucose levels of 100–180 mg/dL are maintained by administration of intravenous insulin (bolus 10 IU and continuous infusion of 2 IU/hour) when the glucose level exceeds 180 mg/dL.

Once the procedure is complete, the heart and aorta are deaired and the aortic cross clamp is removed. Temporary epicardial pacing leads are placed, the surgical site is policed for bleeding and the patient is weaned from CPB. On satisfactory termination from CPB, the cannulas are removed and the patient is administered protamine sulfate to reverse heparin anticoagulation at a dose indicated by the Hepcon system. Full heparin reversal is confirmed by a heparin level assay and ACT measurement. Chest tubes are inserted and the sternum is approximated according to procedure and surgeon preference.

After surgery, patients are transferred to the cardiac surgical intensive care unit (CSICU). Standardised protocols for temperature, sedation, pain, glucose and haemodynamic management are followed. On CSICU arrival, active rewarming using a forced-air warming device is performed. Propofol 2 mg/kg/hour, ketamine 0.5 mg/kg/hour or dexmedetomidine 0.5–1.5 µg/kg/min are administered and titrated to achieve appropriate sedation. Pain control is achieved with the use of multimodal regimens (intravenous opioids, acetaminophen and non-steroidal antiinflammatory drugs). Within the first 72 hours, blood glucose levels are monitored every 4 hours and intravenous insulin may be used to maintain glucose levels between 100 and 180 mg/dL. Volume status and haemodynamic parameters are continuously monitored throughout the patient’s CSICU stay by arterial line and PAC. If needed, vasopressors are administered to achieve the following haemodynamic targets: CI >2.2 L/min/m², MAP >65 mm Hg and SvO₂ >65%. CI, pulmonary vascular resistance and systemic vascular resistance are recorded every 4 hours until test gas suspension. The pRBCs are transfused when Hb <7 g/dL. Urinary output is recorded hourly via urinary catheter. The ICU team may administer furosemide intravenously in the presence of oliguria only after optimisation of haemodynamic parameters, volume status and assurance of no urinary catheter blockage. No nephrotoxic agents (eg, intravenous contrast or hydroxyethyl starch products) are administered as recommended by the KDIGO guidelines.

Gas delivery

After PAC insertion, patients are randomly allocated to the intervention group (80 ppm NO) or the control group (N₂). Using commercially available tanks of N₂ or NO (Airgas, Radnor Township, Pennsylvania) and volumetrically calibrated flowmeters, pure N₂ (placebo) or 850 ppm NO gas in N₂ is mixed with pure O₂ or air. In the NO group, a final concentration of 80 ppm NO is obtained. Test gas administration starts at the onset of CPB and lasts for 24 hours. The test gas is administered via the CPB machine into the sweep gas of the CPB oxygenator by regulating the tank as follows:

\[
\text{NO tank flow (L/min) = } \frac{\text{sweep gas flow (L/min) } \times \text{ NO concentration (80 ppm)}}{\text{NO tank concentration (850 ppm)}}
\]

At the end of the CPB, once ventilation is resumed, test gas is delivered via the inspiratory limb of the anaesthetic or mechanical ventilator circuit, and thereafter via the...
mechanical ventilator in the CSICU. The concentration of NO is regulated by using a medical gas blender. When patients are extubated, they breathe test gas via a face-mask or nasal prongs. NO and nitrogen dioxide (NO₂) levels are monitored through in-line NO/NO₂ sensors (Alphasense, Great Notley, Essex, UK). Met-Hb levels and SpO₂ are continuously measured using a peripheral pulse co-oximeter (Masimo Rainbow Set Technology). Schemas illustrating methods of NO and N₂ gas delivery and NO/NO₂ monitoring both during surgery and in the CSICU are reported in figures 3 and 4.

Abrupt discontinuation of inhaled NO may lead to rebound pulmonary hypertension. This is characterised by worsening oxygenation and increased PAP, resulting in hypoxemia, systemic hypotension, bradycardia and right ventricular failure. For these reasons, after 24 hours, NO is weaned and discontinued while carefully monitoring haemodynamics using the PAC. NO weaning protocols at our institution consists of the following:

- Decreasing NO to a half dose and maintaining this dose for 5 min.
- Further decreasing NO dose to 5 ppm and maintaining this dose for 5 min.
- Complete discontinuation of NO if no pulmonary hypertension rebound occurs and haemodynamics are stable for 10 min after NO gas suspension.

If at any time during the weaning protocol a patient experiences:

- Worsening hypotension (systolic blood pressure, SBP <90 mm Hg) requiring the initiation of an intravenous infusion of vasopressor agents or, in patients already receiving vasopressors before NO weaning, a 50% increase of the dose of the vasopressors.
- Worsening hypoxemia requiring an FiO₂ increase of more than 0.2 or a positive end expiratory pressure (PEEP) increase of more than 5 cm H₂O.
- mPAP increase of more than 20% of the value measured before the initiation of the NO weaning.
- A CI decrease below 1.5 L/min/m² in the presence of a mPAP over 25 mm Hg.

A respiratory therapist (RT) resets the NO to the lowest level at which the patient was stable and notifies
the principal investigator (PI.) and the CSICU attending physician.

Failure of NO weaning is established when one of the above complications occurs.

Blood and urine collection
To assess the extent of haemolysis and the renal-protective properties of NO administration, plasma samples for plasma free Hb, NO consumption, NO metabolites and serum creatinine measurements are collected immediately before starting the surgical procedure, 15 min after the end of CPB, 24 hours after surgery and 48 hours after surgery.\(^{15} \) Additional blood samples for serum creatinine measurements are collected once a day for 7 days following the cardiac procedure or until discharge if the patient is discharged before day 7. Finally, a blood sample for serum creatinine is collected 6 weeks after surgery. Five urine samples are collected for urinary biomarkers of kidney injury (immediately before starting the surgical procedure, 15 min after the end of CPB, and at 24 hours, 48 hours and 6 weeks after surgery).\(^{46-48} \) After centrifugation, all specimens are coded, snap frozen with liquid nitrogen and stored on designated shelves in a −80°C freezer.

Outcomes
Primary outcome
The primary endpoint of this therapeutic trial is to determine whether there is a difference in AKI incidence between the control group (receiving N\(_2\)) versus the intervention group (receiving NO). AKI is defined by KDIGO criteria as an abrupt (within 48 hours) reduction in kidney function correlated to an absolute increase in serum creatinine of 0.3 mg/dL or more (≥26.5 µmol/L) or a percentage increase in serum creatinine of 50% or more (1.5-fold from baseline) at any time during the first 7 days after surgery or a urinary output <0.5 mL/Kg/h for >6 hours.\(^{49} \)

Figure 4 Schema of the NO delivery systems in the cardiac surgical intensive care unit. (A) Figure illustrating how the NO or N\(_2\) is delivered through the mechanical ventilator at bedside in the intensive care unit. Tanks of pure N\(_2\) are used in the control group and tanks of 850 ppm NO in N\(_2\) are used in the intervention group. Test gas is blended with medical air and enters the air inlet of the ventilator. The high pressure O\(_2\) hose is directly connected to the ventilator. If there is any change of FiO\(_2\), the amount of NO/N\(_2\) delivered is regulated by the RT by adjusting the blender setting and the ventilator FiO\(_2\) setting, ensuring that the patient is still receiving the target concentration of 80 ppm NO. The mixture obtained is then scrubbed of NO\(_2\) through a large volume scavenger and a small volume scavenger placed in series on the inspiratory limb of the circuit. The final amount of NO and NO\(_2\) delivered is periodically analysed with a NO/NO\(_2\) analyser directly before the mixture is inhaled by the patient. (B) Figure illustrating how the NO or N\(_2\) is delivered into the high flow nasal cannula device. The test gas is delivered to the system by placing ‘Y’ adaptor before the humidifier. A commercially available blender mixes O\(_2\) and medical air and is regulated by the RT to reach the target FiO\(_2\). The flow of NO\(_2\) or N\(_2\) is titrated to reach the desired concentration 80 ppm NO or placebo. This mixture is then humidified and heated to a temperature of 34°C. FiO\(_2\), inspired fraction of oxygen; N\(_2\), nitrogen; NO, nitric oxide; O\(_2\), oxygen; ppm, parts per million; RT, respiratory therapist.
Secondary outcomes

Secondary renal outcomes include:
1. AKI severity using the KDIGO stages:
   - Stage 1: serum creatinine increase $\geq 26.5$ $\mu$mol/L ($\geq 0.3$ mg/dL) or increase to 1.5-fold to twofold from baseline or urinary output $<0.5$ mL/kg/hour for 6 hours.
   - Stage 2: serum creatinine increase more than two-fold to threefold from baseline or urinary output $<0.5$ mL/kg/hour for 12 hours.
   - Stage 3: serum creatinine increase more than threefold from baseline or serum creatinine $\geq 254$ $\mu$mol/L ($\geq 24.0$ mg/dL) or urinary output $<0.3$ mL/kg/hour for 24 hours or anuria for 12 hours or a need for renal replacement therapy (RRT).
2. Requirement for RRT following AKI during hospitalisation and at 6 weeks, 90 days and 1 year after surgery.
3. MAKE at 6 weeks after surgery. MAKE is a composite outcome of death, new RRT and worsened renal function (defined as a 25% or greater decline in eGFR).
4. Secondary non-renal outcomes include:
   1. Sequential organ failure assessment (SOFA) score during ICU stay.
   2. Prolonged cardiovascular support defined as the need for vasopressors and inotropic agents, a balloon pump or a ventricular-assist device for more than 48 hours after cardiac surgery.
   3. Maximum hourly vasoactive-inotropic score (VIS) for the first 7 days after surgery and duration of vasopressors and inotropic agents support. VIS is calculated as dopamine dose ($\text{mcg/kg/min}$)+dobutamine dose ($\text{mcg/kg/min}$)+10×epinephrine dose ($\text{mcg/kg/min}$)+10$m\times$milrinone dose ($\text{mcg/kg/min}$)+10$k\times$vasopressin dose (units/kg/min)+10$h\times$norepinephrine dose ($\text{mcg/kg/min}$)+10$m\times$phenylephrine dose ($\text{mcg/kg/min}$).
   4. Duration of mechanical ventilation (hours).
   5. ICU and hospital length of stay.

Safety outcomes

1. Intrahospital mortality and mortality at 6 weeks, 90 days and 1 year after surgery.
2. Non-fatal stroke during hospitalisation and at 6 weeks after surgery.
3. Perioperative and non-perioperative non-fatal myocardial infarction.
4. Postoperative bleeding calculated as the sum of blood loss through thoracic drains from the moment of chest closure over a period of 24 hours.
5. Need for blood transfusions or transfusions with blood products.
6. Postoperative infections (eg, pneumonia, wound infection, endocarditis, central line infection, urinary tract infection, sepsis).
7. Cardiac arrhythmias and other non-cardiac postoperative complications (eg, hepatobiliary disorders, pneumothorax, pleural effusion, vascular disorders).
8. Patients requiring a decrease of NO delivery due to Met-Hb $>5\%$.

Sample size planning

The sample size needed for this trial is calculated based on the primary endpoint: the reduction of AKI incidence in the NO treated group (intervention group) compared with the N$_2$ group (control group). In a RCT conducted at the University of Muenster (Germany), Meersch et al showed that implementation of a KDIGO CT surgery ‘bundle’ as recommended by the KDIGO guidelines successfully reduced the incidence of CPB-associated AKI from 71.7% to 55.1%. At Massachusetts General Hospital (MGH), the use of the KDIGO guidelines is part of standard care and the CPB-associated AKI rate is similar (55% as observed in a 1-year chart review performed by the investigators for surgery requiring CPB $>90$ min (data not shown)). In a prior trial we conducted in China, we found a 22% relative risk reduction in the incidence of AKI and a 42% relative risk reduction of stage 3 CKD at 1 year in the NO treated group. In this study, we estimate a greater reduction in the incidence of AKI (35% relative risk reduction) because we anticipate that an American population with endothelial dysfunction will benefit more from NO treatment. Thus, in the NO group, the incidence of AKI is expected to decrease from 55% to 35.75%. Using a Fisher’s exact test to compare proportions, the sample size needed to detect a difference, assuming a two-sided type I error of 0.05 and a power of 0.8, is 114 patients per group. In order to account for possible dropouts, we have increased our sample size by 10%. The enrolment plan is 250 patients (125 patients in the NO group and 125 patients in the N$_2$ group).

Recruitment

This study is performed at MGH in Boston, Massachusetts, USA. All inpatients and outpatients undergoing
In a report to the Institutional Review Board (IRB).

In this circumstance, the PI.

In critical circumstances when the responding physician

in the overall quality, legitimacy and integrity of the

completion of the study (250 patients enrolled). T

patients enrolled in the study will not be disclosed before

is maintained until 1

cation conduct assessment of study outcomes. Blinding

sible for gas tank preparation and test gas delivery and

the treatment. This unblinded clinician is solely respon-

clinician administering the test gas remains unblinded to

assignment group. For safety and gas monitoring, the

OR and at the bedside are masked and cannot be distin-

Marrazzo F, et al. BMJ Open 2019;9:e026848. doi:10.1136/bmjopen-2018-026848

Randomisation and treatment allocation
To ensure balance between study groups with respect to

the likelihood of receiving NO after surgery, after the

insertion of a PAC, the patients are stratified by preoper-
mPAP (ie, mPAP ≤30 mm Hg or mPAP ≥30 mm Hg) then

then allocated into the two study groups. The randomis-

ation sequence is created by an independent statistician

using Stata Statistical Software: Release V.14 and then

uploaded on the MGH Research Electronic Data Capture
(REDCap) application.61 A predetermined block random-

isation method (fixed block size of 10) is used to ensure

equal distribution of participants to treatment arms. A

physician with no clinical involvement in providing care

for the enrolled patients will conduct the randomisation

procedure throughout the study by using the randomisa-

tion function provided by REDCap. Thus, the randomisa-

conducted without any influence from clinicians

providing care for the patients or from statisticians or

outcome assessors.

Blinding
The NO and N2 tanks and the gas delivery systems in the

OR and at the bedside are masked and cannot be distin-

guished on the basis of appearance. This allows to keep

participants, clinicians and investigators blind to the

assignment group. For safety and gas monitoring, the

clinician administering the test gas remains unblinded to

the treatment. This unblinded clinician is solely respon-

sible for gas tank preparation and test gas delivery and

monitoring. Assessors who are blind to the treatment allo-

cation conduct assessment of study outcomes. Blinding

is maintained until 1 year follow-up. The allocation of

patients enrolled in the study will not be disclosed before

completion of the study (250 patients enrolled). To main-

tain the overall quality, legitimacy and integrity of the

clinical trial, unblinding of the test gas may occur only in

critical circumstances when the responding physician

prescribes initiation of NO. In this circumstance, the PI

fully documents and explains the reasons for unblinding

in a report to the Institutional Review Board (IRB).

Data analysis
All trial outcomes will be evaluated using an intention-to-
treat analysis plan. Hypothesis testing will be performed

using a two-sided significance level (type I error) of α=0.05.

Sensitivity analyses per group of treatment will also be

performed and compared with the intention-to-treat anal-

ysis results. The incidence of AKI (primary endpoint) and

postoperative adverse events after prolonged CPB will be

reported in terms of relative risk with 95% CI in the treat-

ment versus the control group. The median differences

(NO group vs control group) with 95% CI will describe

differences in continuous perioperative characteristics

and continuous postoperative outcomes.

An unadjusted analysis of the primary endpoint will be

performed by means of Fisher’s exact test comparing

incidence of AKI in the NO group against the control

(placebo) group. Multivariate logistic regression will be

performed to determine if treatment with NO reduces

incidence of AKI after adjusting for eGFR, age, sex and

EuroSCORE II.

Secondary and exploratory endpoints will be addressed

using appropriate tests for each outcome. Categorical

variables will be compared between the two groups using

Fisher’s exact test or X2 as appropriate. Continuous vari-

ables will be compared between the two groups using

Student’s t-test or a Mann-Whitney U test as appropriate.

The change in the laboratory markers over time and

between the two groups will be tested with a mixed effects

modelling. Differences among the groups at each time-

point will be tested using an unpaired Student’s t-test or a

Mann-Whitney U test as appropriate.

Interim analysis
An interim analysis by a Data Safety Monitoring Board
(DSMB) is planned upon reaching 50% of the study

population. The DSMB is composed of three indepen-
dent, multidisciplinary experts (online supplementary
material: Data and Safety Monitoring Board section). An

independent statistician will perform the interim anal-

ysis. The statistician will report the results of the data

analysed to the DSMB in a closed session. The DSMB

will have access to data collected during the hospital stay

during the follow-up visits, including maintenance of

patient confidentiality throughout the study. The DSMB

may recommend terminating the study if at the interim

analysis a significant increase of intrahospital mortality,
mortality at 6 weeks, AKI or need for RRT in either group

(NO group vs control group) with 95% CI will describe

differences in continuous perioperative characteristics

and continuous postoperative outcomes.

All trial outcomes will be evaluated using an intention-to-
treat analysis plan. Hypothesis testing will be performed

using a two-sided significance level (type I error) of α=0.05.

Sensitivity analyses per group of treatment will also be

performed and compared with the intention-to-treat anal-

ysis results. The incidence of AKI (primary endpoint) and

postoperative adverse events after prolonged CPB will be

reported in terms of relative risk with 95% CI in the treat-

ment versus the control group. The median differences

(NO group vs control group) with 95% CI will describe

differences in continuous perioperative characteristics

and continuous postoperative outcomes.

An unadjusted analysis of the primary endpoint will be

performed by means of Fisher’s exact test comparing

incidence of AKI in the NO group against the control

(placebo) group. Multivariate logistic regression will be

performed to determine if treatment with NO reduces

incidence of AKI after adjusting for eGFR, age, sex and

EuroSCORE II.

Secondary and exploratory endpoints will be addressed

using appropriate tests for each outcome. Categorical

variables will be compared between the two groups using

Fisher’s exact test or X2 as appropriate. Continuous vari-

ables will be compared between the two groups using

Student’s t-test or a Mann-Whitney U test as appropriate.

The change in the laboratory markers over time and

between the two groups will be tested with a mixed effects

modelling. Differences among the groups at each time-

point will be tested using an unpaired Student’s t-test or a

Mann-Whitney U test as appropriate.

Interim analysis
An interim analysis by a Data Safety Monitoring Board
(DSMB) is planned upon reaching 50% of the study

population. The DSMB is composed of three indepen-
dent, multidisciplinary experts (online supplementary
material: Data and Safety Monitoring Board section). An

independent statistician will perform the interim anal-

ysis. The statistician will report the results of the data

analysed to the DSMB in a closed session. The DSMB

will have access to data collected during the hospital stay

during the follow-up visits, including maintenance of

patient confidentiality throughout the study. The DSMB

may recommend terminating the study if at the interim

analysis a significant increase of intrahospital mortality,
mortality at 6 weeks, AKI or need for RRT in either group

(NO group vs control group) with 95% CI will describe

differences in continuous perioperative characteristics

and continuous postoperative outcomes.

All trial outcomes will be evaluated using an intention-to-
treat analysis plan. Hypothesis testing will be performed

using a two-sided significance level (type I error) of α=0.05.

Sensitivity analyses per group of treatment will also be

performed and compared with the intention-to-treat anal-

ysis results. The incidence of AKI (primary endpoint) and

postoperative adverse events after prolonged CPB will be

reported in terms of relative risk with 95% CI in the treat-

ment versus the control group. The median differences

(NO group vs control group) with 95% CI will describe

differences in continuous perioperative characteristics

and continuous postoperative outcomes.

An unadjusted analysis of the primary endpoint will be

performed by means of Fisher’s exact test comparing

incidence of AKI in the NO group against the control

(placebo) group. Multivariate logistic regression will be

performed to determine if treatment with NO reduces

incidence of AKI after adjusting for eGFR, age, sex and

EuroSCORE II.

Secondary and exploratory endpoints will be addressed

using appropriate tests for each outcome. Categorical

variables will be compared between the two groups using

Fisher’s exact test or X2 as appropriate. Continuous vari-

ables will be compared between the two groups using

Student’s t-test or a Mann-Whitney U test as appropriate.

The change in the laboratory markers over time and

between the two groups will be tested with a mixed effects

modelling. Differences among the groups at each time-

point will be tested using an unpaired Student’s t-test or a

Mann-Whitney U test as appropriate.

Interim analysis
An interim analysis by a Data Safety Monitoring Board
(DSMB) is planned upon reaching 50% of the study

population. The DSMB is composed of three indepen-
dent, multidisciplinary experts (online supplementary
material: Data and Safety Monitoring Board section). An

independent statistician will perform the interim anal-

ysis. The statistician will report the results of the data

analysed to the DSMB in a closed session. The DSMB

will have access to data collected during the hospital stay

during the follow-up visits, including maintenance of

patient confidentiality throughout the study. The DSMB

may recommend terminating the study if at the interim

analysis a significant increase of intrahospital mortality,
mortality at 6 weeks, AKI or need for RRT in either group

(NO group vs control group) with 95% CI will describe

differences in continuous perioperative characteristics

and continuous postoperative outcomes.

All trial outcomes will be evaluated using an intention-to-
treat analysis plan. Hypothesis testing will be performed

using a two-sided significance level (type I error) of α=0.05.

Sensitivity analyses per group of treatment will also be

performed and compared with the intention-to-treat anal-

ysis results. The incidence of AKI (primary endpoint) and

postoperative adverse events after prolonged CPB will be

reported in terms of relative risk with 95% CI in the treat-

ment versus the control group. The median differences

(NO group vs control group) with 95% CI will describe

differences in continuous perioperative characteristics

and continuous postoperative outcomes.
specific privileges to members of the study team for data import/export. Quality and integrity of the data collected are optimised by using software properties such as logic checks and validation of data fields (ie, reference range, valid or invalid values). Warnings and error messages alert the co-investigator of missing data or data entries that do not match the requirements set up in the data-entry field. Also, the co-investigators manually perform weekly checks to ensure data consistency. During these periodical checks, all errors detected by the study team related to data collection and data entry are summarised in a data query report. The report is sent to the PI following the enrolment of every five patients. It is the responsibility of the PI to check the original forms for inconsistency, make corrections by modifying the original forms when necessary and enter a response to the query. Strict confidentiality is maintained by the research team at all times. All forms are and will be kept in a secure, locked cabinet with limited access for at least 5 years after study completion.

**Trial management**

Study team physicians are responsible for screening all inpatients and outpatients undergoing a scheduled procedure. The number of eligible, consented, enrolled and randomised patients is recorded in addition to the reasons for non-participation in the trial.

During their hospital stay, patients are closely monitored and all outcomes are recorded. For this reason, no missing endpoints are expected. After discharge, all patients have a scheduled follow-up visit with the cardiac surgeon 6 weeks after surgery. The day before their appointment, the patient is contacted by a member of the study staff to remind them that a member of the team will collect research data during their visit. This is done by a phone call (or email if unreachable by phone). At the end of the visit with the cardiac surgeon, blood and urine samples are collected for kidney function assessment and a questionnaire regarding medical and surgical complications and quality of life is given. Patients are then called at 90 days and 1 year after surgery to evaluate mid-term and long-term outcomes. To avoid missing follow-ups, a minimum of three calls are attempted by the study team. Calls are made at different times and dates in an attempt to increase the probability of contacting patients. Phone numbers provided by the patient on the screening day are used. If the study team is still unable to contact the patient despite the several phone call attempts, a letter is sent to the home address provided by the patient at their initial screening visit. If all attempts do not provide contact with the patient, a member of the study team may call the patient’s primary care physician or another healthcare provider to obtain information regarding the patient’s condition (eg, deceased). Based on trials previously performed in the Department of Surgery at the MGH, we expect a loss to follow-up of 10%, 15% and 20% at 6 weeks, 90 days and 1 year, respectively.

**Trial risks**

Due to the instability of NO, there are risks associated with its use that must be considered. NO reacts slowly with oxygen to form NO₂, which may cause airway inflammation and damage to lung tissues. Moreover, NO oxidises ferrous Hb to form Met-Hb, which is unable to transport and release oxygen to tissues. However, cyanosis in healthy patients does not appear until Met-Hb levels are 15%–20%. The binding of NO to Hb is a rapidly reversible reaction, with a half-life of 15–20 min after NO discontinuation. The side effects and adverse events related to NO delivery are well reported in the literature. In **Table 1**, we summarised eight clinical trials that recorded and reported adverse events associated with NO gas in newborn, paediatric and adult populations. Based on the present literature and Food and Drug Administration reports, the risks of breathing NO at 80 ppm for 24 hours are minimal when Met-Hb levels and NO/NO₂ delivery levels are carefully monitored. To improve safety, in the present trial, NO is administered and monitored by trained respiratory therapists. The IRB for this study requested monitoring and maintaining levels of NO₃ breathing below 5 ppm. We previously tested and found that our delivered circuits do not exceed delivering 1.5 ppm of NO₃ when 80 ppm of NO gas is delivered at 90% of FiO₂. Met-Hb is continuously monitored by non-invasive co-oximetry. If Met-Hb levels exceed 5% of circulating Hb, the concentration of NO delivered is halved from 80 ppm to 40 ppm and closely monitored until a reduction occurs. If Met-Hb levels persist above 5%, NO is progressively halved until a reduction below 5% occurs.

**Criteria for patient discontinuation**

The criteria for patient discontinuation from the study are as follows.

| Voluntary discontinuation by a patient. |
| Exiting the protocol for safety reasons based on the judgement of the clinical or research staff. Specific safety reasons include: (1) acute worsening of hypotension defined as a decrease in MAP of >20 mm Hg that is not attributable to other causes (such as hypovolemia, haemorrhage or sepsis), but is generally due to worsening of left ventricular failure, (2) sudden worsening of hypoxemia defined as a decrease of SpO₂ to <80% while breathing 100% oxygen and not attributable to other causes (such as pulmonary oedema, ARDS or pulmonary embolism) and (3) an increase in NO₂ levels >5 ppm from baseline. |

**Patient and public involvement**

Patients were not directly involved in the study design and recruitment, and did not contribute to the development of the research questions and outcomes. At the end of the trial, on request, results will be provided to the study participants and/or their family members and then published on clinicaltrials.gov.
Enrolment to date
As of May 2019, 161 patients have been enrolled in the study. Assuming that we recruit about eight patients per month, we anticipate completing the recruitment of 250 patients by May 2020.

Ethics and dissemination
The current trial was approved by the International Review Board (IRB) in August 2016. Further amendments of the study protocol have been performed and clinical trials.gov has been updated accordingly. Analysis of the outcomes of the study (primary, secondary and exploratory outcomes) will be performed when the enrolment of 250 patients is complete. These results will be published in a primary paper, which will be directed to a peer-reviewed journal and may be presented as a poster and/or through oral communication at scientific conferences focused on cardiac surgery, nephrology, anaesthesia and critical care medicine.

CONCLUSION
This trial is evaluating whether 24 hours administration of NO gas reduces the incidence of AKI after prolonged CPB in patients with signs and symptoms of endothelial dysfunction. The results obtained by this trial may also represent further progress of the scientific community in evaluating the systemic beneficial properties of exposing plasma to NO gas.

Author affiliations
1Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
2Department of Medicine, Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts, USA
3Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
4Department of Cardiac surgery, Massachusetts General Hospital, Boston, Massachusetts, USA
5Department of Surgery, Cardiac Surgery, Perfusion Services, Massachusetts General Hospital, Boston, Massachusetts, USA
6Respiratory Care Services, Massachusetts General Hospital, Boston, Massachusetts, USA
7Respiratory Care Services, Boston Medical Center, Boston, Massachusetts, USA
8Department of Respiratory Care, Massachusetts General Hospital, Boston, USA
9Department of Anesthesiology, Harvard University, Boston, USA
10Department of Medicine, Pulmonary and Critical Care Unit, Massachusetts General Hospital, Boston, Massachusetts, USA
11Department of Medicine, Division of Renal Medicine, Brigham and Women’s Hospital Department of Medicine, Boston, Massachusetts, USA

Acknowledgements The clinical perfusionists of the Department of Cardiac Surgery, Perfusion Services, Massachusetts General Hospital (Boston, Massachusetts, USA). The respiratory therapy staff, the nursing staff and the physicians of the Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, USA. The nursing staff and the physicians of the department of Cardiac Surgery, Massachusetts General Hospital (Boston, MA, USA). The nursing staff of the pre-admission testing area, Massachusetts General Hospital.

Table 1: Summary of prior selected studies that reported adverse events related to NO administration

| Authors          | Patients (n) | Age group (newborn, paediatric, adult) | NO (ppm) | Time of exposure | Adverse events                                                                 |
|------------------|--------------|----------------------------------------|----------|------------------|--------------------------------------------------------------------------------|
| Van Meurs et al[^3] | 210          | Premature newborns <34 weeks gestational age (26±2 gestational weeks) | 5–10     | 10–14 hours      | NO$_2$ >5 ppm in two infants; Met-Hb >8% in one infant. No resulting complications were reported. |
| Stork et al[^6]  | 114          | Newborns >34 gestational weeks and <14 days old (39.3±1.8 gestational weeks) | 20–80    | <14 days         | Met-Hb >5% in 11 infants. No resulting complications were reported. A dose of 100 ppm NO was given to two infants for 36 and 60 min, respectively. NO$_2$ levels in the second infant elevated to 5.1 ppm. NO$_2$ and Met-Hb levels decreased after NO concentration returned to 80 ppm. |
| Roberts et al[^7] | 30           | Newborns >37 gestational weeks (39.8±1.5 gestational weeks) | 80       | <8.5 days        | Met-Hb elevated to 18.2% in one infant. The later clinical course was uneventful. |
| James et al[^71] | 101          | Paediatric (1–43 months old) | 20       | 1–3 hours        | None related to NO delivery. |
| Cueto et al[^72] | 40           | Paediatric (15 days old–17 years old) | 4–30     | hours to days    | Rebound effects of NO withdrawal reported in two patients. |
| Lei et al[^17]   | 117          | Adult >18 years old (48.7±9.5 years old) | 80       | 24 hours        | None related to NO delivery. |
| Rossaint et al[^73] | 9         | Adult (17–46 years old) | 5–20    | 3–53 days       | None related to NO delivery. |
| Taylor et al[^14] | 192          | Adult >18 years old (50±17 years old) | 5        | <28 days        | 66 reported infections in the NO group and 41 in the control group. Infections deemed unrelated to NO gas administration. No further complications were reported. |

Data of age are presented as mean±SD or range.
Met-Hb, ferric methaemoglobin; NO, nitric oxide; NO$_2$, nitrogen dioxide.
Hospital (Boston, MA, USA). Francesco Nordio, PhD (Research Associate in Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA) for his role of independent statistician of this trial. Kelly Larson, RN, and Christopher Chenelle, BA, for language editing.

Contributors Authorship for this trial will be given to key personnel involved in trial design, personnel training, recruitment, data collection, statistical plan and data analysis. There are no publication restrictions. LB, WMZ, JBV, TBT, NR, EAB, TMB, DF, ER, FM and FI were responsible for conceptualising trial design. LB managed patient safety protocol. LB, FM, SS, FZ, CX, GL and TSL are responsible for recruitment, enrollment and data collection. RM, HZ and EAB are responsible for power calculation, statistical plan and data analysis. LB, KS, SM, WDR, PW and RMK trained personnel for the clinical trial and built systems for nitric oxide delivery and monitoring. All authors have critically revised the study protocol and approved the final version. All authors agree to be accountable for the accuracy and integrity of all aspects of this trial.

Funding Department of Anesthesiology, Critical Care and Pain Medicine (Massachusetts General Hospital, Boston, Massachusetts, USA) and the National Institutes of Health (National Heart, Lung, and Blood Institute K23 HL128882-01A1).

Competing interests FM and LB salaries are partially supported by NIH/NHLBI 1 K23 HL128882-01A1. JB is co-inventor on patents that are assigned to Partners Healthcare. RMK is a consultant for Medtronic and Orange Medical and has received research grants from Medtronic and Venner Medical.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES
1. Wrobel K, Stevens SR, Jones RH, et al. Influence of baseline characteristics, operative conduct, and postoperative course on 30-day outcomes of coronary artery bypass grafting among patients with left ventricular dysfunction. Circulation 2015;132:720–30.
2. Karkouti K, Wijeyesundera DN, Yau TM, et al. Acute kidney injury after cardiac surgery: focus on modifiable risk factors. Circulation 2009;119:495–502.
3. Kumar AB, Suneja M. Cardiopulmonary bypass-associated acute kidney injury. Anesthesiology 2011;114:964–70.
4. Legouis D, Galichon P, Bataille A, et al. Rapid Occurrence of Chronic Kidney Disease in Patients Experiencing Reversible Acute Kidney Injury after Cardiac Surgery. Anesthesiology 2017;126:39–46.
5. Hobson CE, Pavas S, Segal MS, et al. Acute kidney injury is associated with increased long-term mortality after cardiothoracic surgery. Circulation 2009;119:2444–53.
6. Kertai MD, Zhou S, Karhausen JA, et al. Platelet Counts, Acute Kidney Injury, and Mortality after Coronary Artery Bypass Grafting Surgery. Anesthesiology 2016;124:339–52.
7. Billings FT, Hendricks PA, Schildcrout JS, et al. High-dose perioperative atorvastatin and acute kidney injury following cardiac surgery: a randomized clinical trial. JAMA 2016;315:877.
8. Bove T, Zangrillo A, Guarracino F, et al. Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial. JAMA 2014;312:2244.
9. Dieleman JM. Intraoperative high-dose dexamethasone for cardiac surgery. JAMA 2016;315:877.
10. Dardashti A, Ederth P, Algotssson L, et al. Erythropoietin and protection of renal function in cardiac surgery (the EPRICS Trial). Anesthesiology 2014;121:582–90.
11. Wang Y, Bellomo R. Cardiac surgery-associated acute kidney injury: risk factors, pathophysiology and treatment. Nat Rev Nephrol 2017;13:697–711.
12. Vermeulen Windstrand IC, Snoeijis MG, Hanssen SJ, et al. Hemolysis is associated with acute kidney injury during major aortic surgery. Kidney Int 2010;77:913–20.
13. Vermeulen Windstrand IC, de Wit NC, Sertorio JT, et al. Hemolysis during cardiac surgery is associated with increased intravascular nitric oxide consumption and perioperative kidney and intestinal tissue damage. Front Physiol 2014;5:340.
14. Mammadov LS, Mamo LB, Smith PB, et al. Cardiopulmonary bypass is associated with hemolysis and acute kidney injury in neonates, infants, and children. Pediatr Crit Care Med 2014;15:e111–9.
15. Rezoagli E, Ichihose F, Strelow S, et al. Pulmonary and systemic vascular resistances after cardiopulmonary bypass: role of hemolysis. J Cardiothorac Vasc Anesth 2017;31:505–15.
16. Minnci PC, Deans KJ, Zhi H, et al. Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by deoxymethemoglobin. J Clin Invest 2005;115:3409–17.
17. Lei C, Berra L, Rezoagli E, et al. Nitric oxide decreases acute kidney injury and stage 3 chronic kidney disease after cardiac surgery. Am J Resp Crit Care Med 2018;198:1279–87.
18. Vallance P, Coller J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989:2:997–1000.
19. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J 2012;33:829–37.
20. Vanhoutte PM, Shimokawa H, Tang EHC, et al. Endothelial dysfunction and vascular disease. Acta Physiol 2009;196:193–222.
21. Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006;113:1708–14.
22. Ruan SY, Huang TM, Wu HY, et al. Inhaled nitric oxide therapy and risk of renal dysfunction: a systematic review and meta-analysis of randomized trials. Crit Care 2015;19:137.
23. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. Abstract. Kidney Int Suppl 2012;2:6.
24. Meersch M, Schmid J, Hoffmeier A, et al. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med 2017;43:1551–61.
25. Lameire N, Kellum JA, KDIGO AKI Guideline Work Group. Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (Part 2). Crit Care 2013;17:205.
26. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxic vasodistraction induced by acetylecholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1002–8.
27. Patel AR, Hui H, Kuv J, et al. Modestly overweight women have vascular endothelial dysfunction. Clin Cardiol 2009;32:269–73.
28. Panza JA, Quyyumi AA, Brush JJ, et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323:22–7.
29. Johnstone MT, Greager SJ, Scales KM, et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993;88:2510–6.
30. Chowienczyk PJ, Watts GF, Cockcroft JR, et al. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypertension. Circulation 1992;86:1430–2.
31. Zeiher AM, Drexler H, Wollschläger H, et al. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991;83:391–401.
32. Celemajer DS, Sorensen KE, Spiegelhalter DJ, et al. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 1994;24:711–6.
33. Celemajer DS, Sorensen KE, Georgakopoulos D, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelial-dependent dilation in healthy young adults. Circulation 1993;88:2149–55.
34. Celemajer DS, Adams MR, Clarkson P, et al. Passive smoking and impaired endothelium-dependent arterial dilation in healthy young adults. N Engl J Med 1996;334:150–5.
35. Taddie S, Virdis A, Mattei P, et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995;91:1981–7.
36. Pino RM, Albrecht MA, Bittner EA, et al. Clinical anesthesia procedures of the Massachusetts General Hospital. 9th edn. Boston: LWW, 2015.
37. Prichop LS, Gugino LD, John ER, et al. The Patient State Index as an indicator of the level of hypnosis under general anaesthesia. Br J Anaesth 2004;92:393–9.
38. Kim K, Ball C, Grady P, et al. Use of del nido cardioplaegia for adult cardiac surgery at the Cleveland clinic: perfusion implications. J Extracorp Technol 2014;46:317–23.
39. Carson JL, Guyatt G, Heddle NM, et al. Clinical practice guidelines from the AABB. JAMA 2005;293:9.
40. Atz AM, Adatia I, Wessel DL. Rebound pulmonary hypertension after inhalation of nitric oxide. Ann Thorac Surg 1996;62:1759–64.
41. Black SM, Heidersbach RS, McMullan DM, et al. Inhaled nitric oxide inhibits NOS activity in lambs: potential mechanism for rebound pulmonary hypertension. *Am J Physiol* 1999;277:H1849–H1856.

42. Schulze-Neck I, Werner H, Penny DJ, et al. Acute ventilatory restriction in children after weaning off inhaled nitric oxide: relation to rebound pulmonary hypertension. *Intensive Care Med* 1999;25:76–80.

43. Berra L, Pincroll R, Stowell CP, et al. Autologous transfusion of stored red blood cells increases pulmonary artery pressure. *Am J Crit Care Med* 2001;160:719–27.

44. Meyer C, Heiss C, Drexhage C, et al. Hemodialysis-induced release of hemoglobin limits nitric oxide bioavailability and impairs vascular function. *J Am Coll Cardiol* 2010;55:454–9.

45. Wang X, Tanus-Santos JE, Reiter CD, et al. Biological activity of nitric oxide in the peritoneal compartment. *Proc Natl Acad Sci U S A* 2004;101:11477–82.

46. Vaidya VS, Ramirez V, Ichimura T, et al. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury after cardiac surgery. *Am J Physiol Renal Physiol* 2006;290:F517–29.

47. Vaidya VS, Waiker SS, Ferguson MA, et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. *Clin Transl Sci* 2008;1:200–8.

48. Koyner JL, Vaidya VS, Bennett MR, et al. Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. *Clin J Am Soc Nephrol* 2010;5:2154–65.

49. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. *Nephron Clin Pract* 2013;127:89–93.

50. Billings FT, Shaw AD. Clinical trial endpoints in acute kidney injury. *Nephron Clin Pract* 2014;127:89–93.

51. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA* 2016;315:801–10.

52. Nguyen HV, Havalad V, Aponte-Patel L, et al. Temporary biventricular pacing decreases the vasoactive-inotropic score after cardiac surgery: a study of a randomized clinical trial. *J Thorac Cardiovasc Surg* 2013;146:296–301.

53. Landori G, Lomivorotov VV, Alvaro G, et al. Levosimendan for hemodynamic support after cardiac surgery. *N Engl J Med* 2017;376:290–7.

54. Nashef SA, Roques F, Sharples LD, et al. EuroSCORE II. *Eur J Cardiothorac Surg* 2012;41:734–45.

55. Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). *Crit Care Med* 2001;29:1370–9.

56. Rudolph JL, Inouye SK, Jones RN, et al. Delirium: an independent predictor of functional decline after cardiac surgery. *J Am Geriatr Soc* 2010;58:643–9.

57. Katz S, Down TD, Cash HR, et al. Progress in development of the index of ADL. *Gerontologist* 1970;10:20–30.

58. Hays RD, Bjorner JB, Revicki DA, et al. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. *Qual Life Res* 2009;18:873–80.

59. PROMIS. Scoring at the MID. *Qual Life Res* 2014.

60. Thysgesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. *Eur Heart J* 2012;33:2551–67.

61. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;42:377–81.

62. Agency for Toxic Substances and Disease Registry. Medical management guidelines for nitrogen oxides (NO, NO2, and others). http://www.atsdr.cdc.gov/mmg/mmg.asp?id=394&tid=69.

63. Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: etiology, pharmacology, and clinical management. *Ann Emerg Med* 1999;34:646–56.

64. Center for drug evaluation and research. INOmax (nitric oxide) for inhalation (Application number: NDA 20845/ S-14). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/20845Orig1s014.pdf.

65. Schedin U, Frostell CG, Gufeldsson LE. Formation of nitrogen dioxide from nitric oxide and their measurement in clinically relevant circumstances. *Br J Anaesth* 1999;82:182–92.

66. Feiner JR, Blickler PE. Improved accuracy of methemoglobin detection by pulse CO-oximetry during hypoxia. *Anesth Analg* 2010;111:1160–7.

67. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009;150:604.

68. Van Meurs KP, Wright LL, Ehrkenkranz RA, et al. Inhaled nitric oxide for premature infants with severe respiratory failure. *N Engl J Med* 2005;353:13–22.

69. Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. *N Engl J Med* 1997;336:597–604.

70. Roberts JD, Fineman JR, Morin FC, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. *N Engl J Med Summer Ed* 1997;336:805–10.

71. James C, Miller J, Horton S, et al. Nitric oxide administration during paediatric cardiopulmonary bypass: a randomised controlled trial. *Intensive Care Med* 2016;42:1744–52.

72. Cueto E, Lopez-Herce J, Sanchez A, et al. Life-threatening effects of discontinuing inhaled nitric oxide in children. *Acta Paediatr* 1997;86:1337–9.

73. Rossaint R, Falke KJ, Lopez F, et al. Inhaled nitric oxide for the adult respiratory distress syndrome. *N Engl J Med* 1993;328:399–405.

74. Taylor RW, Zimmerman JL, Dellingr RP, et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. *JAMA* 2004;291:1603–8.